Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Norovirus vaccine recombinant monovalent - Takeda

Drug Profile

Norovirus vaccine recombinant monovalent - Takeda

Alternative Names: Norovirus dry powder vaccine - Takeda; Norovirus monovalent VLP vaccine - Takeda; Norwalk virus-like particle vaccine - Takeda

Latest Information Update: 21 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LigoCyte Pharmaceuticals
  • Developer Baylor College of Medicine; Takeda
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Norovirus infections

Most Recent Events

  • 05 Aug 2014 Archimedes Pharma has been acquired by ProStrakan
  • 05 Oct 2012 LigoCyte Pharmaceuticals has been acquired and merged into Takeda
  • 25 Oct 2010 Efficacy & adverse events data from the phase I/II LV01-103 trial in Norovirus infections presented at the (48th Annual Meeting of the Infectious Diseases Society of America (IDSA-2010)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top